pm-01183 and Rhabdomyolysis

pm-01183 has been researched along with Rhabdomyolysis* in 1 studies

Other Studies

1 other study(ies) available for pm-01183 and Rhabdomyolysis

ArticleYear
U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome.
    Clinical lung cancer, 2022, Volume: 23, Issue:8

    Topics: Databases, Factual; Humans; Lung Neoplasms; Rhabdomyolysis; Tumor Lysis Syndrome; United States; United States Food and Drug Administration

2022